Mark D. Pegram, MD

Articles

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Dr Pegram on the Implications and Safety of T-DXd in HR+/HER2-Low and -Ultralow Breast Cancer

June 7th 2024

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.

Future Directions in HR+ Breast Cancer Management

September 7th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

Clinical and Practical Implications of the Breast Cancer Index

September 7th 2022

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer

August 19th 2022

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

Tools to Guide Treatment Decision-Making in HR+ Breast Cancer

August 19th 2022

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.